Complex Medicines: 
A Glance at Novel Drug Delivery Systems

8 June 2021  |  2 - 3PM BST

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.

© Medicines Discovery Catapult 2021. All rights reserved. Read our Privacy Policy


Lipid nanoparticles – so much more than a little fat blob - Yvonne Perrie (University of Strathclyde)
“Bursting with promise” - precision drug delivery with Therapeutic Microbubbles - Louise Coletta (University of Leeds)
Under the radar: alternative delivery of mRNA vaccines - Helen McCarthy (pHion Therapeutics)





Complex Medicines: Understanding Safety & Efficacy
15 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Selection and Characterisation of the Lead
18 May 2021  |  2 - 3PM BST
Register >

Complex Medicines: Ready for the Clinic/Scaling up for Success
22 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Understanding the Interplay with Biological Systems
25 May 2021  |  2 - 3PM BST
Register >

Complex Medicines: Why, What, When? Opportunities and Challenges
11 May 2021  |  2 - 3PM BST
Register >

Dr Sarah Brockbank
Sarah Brockbank is Lead Scientist of External Drug Discovery at the Medicines Discovery Catapult. Here she supports SMEs develop and execute drug discovery projects and provides the project management of virtual preclinical programmes by connecting clients with expertise and capabilities.

Sarah has 30 years’ experience in the pharmaceutical industry. She is a molecular biologist with a focus mainly in target identification & validation and has worked across a broad range of disease areas. Sarah was a Drug Discovery Project Leader at AstraZeneca and she also has extensive experience in collaboration management and project management of large public-private consortia.

At this midpoint in the webinar series, we will hear from the pioneers developing complex medicines and the challenges presented and overcome.

Yvonne Perrie
Yvonne is a Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland. In 1998, Yvonne gained a PhD from the University of London investigating the role of liposomes for DNA vaccine delivery. She then worked in London within a newly established Drug Delivery Company (Lipoxen Technologies Ltd) for two years, developing their liposome drug delivery platform technology prior to moving into Academia to set up my own research group. Yvonne joined Aston University in 2000 and was appointed Professor in Drug Delivery in 2007. She was Head of the Aston Pharmacy School from 2009 – 2016. In 2016, Yvonne moved to the University of Strathclyde as Professor in Drug Delivery and is a Vice Dean (Research) for the Faculty of Science. Her research is multi-disciplinary and focuses on the development of nanomedicines to facilitate the delivery of drugs and vaccines, thus providing practical solutions for current healthcare problems.

Prof. Helen McCarthy
Prof. Helen McCarthy holds the Chair of Nanomedicine in the School of Pharmacy at Queen’s University Belfast and is the CEO of pHion Therapeutics. Prof McCarthy’s research team have focused on the development of non-viral delivery systems for nanomedicine applications. These biomimetic peptide systems are designed to overcome the extra and intracellular barriers, so that the macromolecular payload can be delivered at the destination site in order to exert the optimal therapeutic effect. The wide-spread utility of these delivery systems has led to a spin-out company pHion Therapeutics pHion is currently developing its pipeline of peptide/mRNA vaccines towards the clinic.

Dr Louise Coletta
Louise is a group leader in the Leeds Institute of Medical Research at St James's University Hospital. Her interests lie in the molecular mechanisms of disease and development of novel cancer therapeutics. Her group focuses on pre-clinical evaluation and translation using both in vitro and in vivo models. In recent years, she has worked in a multidisciplinary team with physicists, engineers, clinicians and chemists engaged in the development of therapeutic microbubbles for targeted, triggered drug delivery.